Skip to main content
SpringerLink
Log in

Long-Acting β2 Agonists in the Management of Stable Chronic Obstructive Pulmonary Disease

  • Disease Management
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Long-acting β2 agonist bronchodilators (e.g. formoterol, salmeterol) are a new interesting therapeutic option for patients with chronic obstructive pulmonary disease (COPD).

In the short term, both salmeterol and formoterol appear to be more effective than short-acting β2 agonists, and in patients with stable COPD they are more effective than anticholinergic agents and theophylline.

Regular treatment of patients with COPD with long-acting β2 agonists can induce an improvement in the respiratory function and certain aspects of quality of life. Moreover, salmeterol seems to be better than ipratropium and theophylline in improving lung function at the recommended doses after a long term treatment.

Use of combination therapy of a long-acting inhaled β2 agonist and an anticholinergic agent or theophylline in patients with COPD has not been sufficiently studied. Combination of usual doses of ipratropium or oxitropium with usual doses of salmeterol or formoterol does not appear to improve pulmonary function, but this lack of improvement with the combination should not, in itself, prevent implementation of further therapeutic steps in patients responsive to an anticholinergic agent and/or salmeterol or formoterol administered singly.

Neither formoterol nor salmeterol elicit significant cardiovascular effects in healthy individuals and patients with reversible airway obstruction. However, adverse cardiac events might occur in patients with COPD with pre-existing cardiac arrhythmias and hypoxaemia if they use long-acting β2 agonists, although the recommended single dose of salmeterol 50µg or formoterol 12µg ensures a relatively higher safety margin than formoterol 24µg.

The bronchodilatory effect of long-acting β2 agonists seems to be fairly stable after regular treatment with these bronchodilators. Moreover, pre-treatment with a conventional dose of formoterol or salmeterol does not preclude the possibility of inducing further bronchodilation with salbutamol in patients with partially reversible COPD.

All these findings support the use of long-acting β2 agonist bronchodilators as first-line bronchodilator therapy for the long term treatment of airflow obstruction in patients with COPD. However, since physicians must always choose a drug that is highly efficacious, well tolerated and inexpensive, the cost-effectiveness analysis in relation to other bronchodilators will determine the proper place of long-acting β2 agonists in the long term therapy of stable COPD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the lung health story. JAMA 1994; 272: 1497–505

    Article  PubMed  CAS  Google Scholar 

  2. Cazzola M, Spina D, Matera MG. The use of bronchodilators in stable chronic obstructive pulmonary disease. Pulm Pharmacol Ther 1997; 10: 129–44

    Article  PubMed  CAS  Google Scholar 

  3. The COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52 Suppl. 5: S1–28

    Google Scholar 

  4. Vollmer M, Schmidt EW, Ulmer WI. Wirkdauer und Wirkstarke von Salmeterol, Fenoterol und Salbutamol bei schweren Formen obstruktiver Atemwegserkrankungen. Pneumologie 1995; 49: 528–34

    PubMed  CAS  Google Scholar 

  5. Cazzola M, Santangelo G, Piccolo A, et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1994; 7: 103–7

    Article  PubMed  CAS  Google Scholar 

  6. Cazzola M, Matera MG, Santangelo G, et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. RespirMed 1995; 89: 357–62

    CAS  Google Scholar 

  7. Çelik G, Kayacan O, Beder S, et al. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action. Respiration 1999; 66: 434–9

    Article  PubMed  Google Scholar 

  8. Maesen BLP, Westermann CJJ, Duurkens VAM, et al. Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease. EurRespir J 1999; 13: 1103–8

    CAS  Google Scholar 

  9. Cazzola M, Di Perna F, Califano C, et al. Formoterol Turbuhaler (F) vs salmeterol Diskus (S) in patients with partially reversible stable COPD [abstract]. Am J Respir Crit Care Med 1999; 159: A798

    Google Scholar 

  10. Ramirez-Venegas A, Ward J, Lentine T, et al. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 1997; 112: 336–40

    Article  PubMed  CAS  Google Scholar 

  11. Grove A, Lipworth BJ, Reid P, et al. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive pulmonary disease. Thorax 1996; 51: 689–93

    Article  PubMed  CAS  Google Scholar 

  12. Khoukaz G, Gross NJ. Effects of salmeterol on arterial blood gases in patients with stable chronic obstructive pulmonary disease: comparison with albuterol and ipratropium. Am J Respir Crit Care Med 1999; 160: 1028–30

    PubMed  CAS  Google Scholar 

  13. Schultze-Werninghaus G. Multicenter 1-year trial on formoterol, a new long-acting beta2-agonist, in chronic obstructive airway disease. Lung 1990; 168 Suppl.: 83–9

    Article  PubMed  Google Scholar 

  14. Thomson NC, Angus R, Quebe-Fehling E, et al. Efficacy and tolerability of formoterol in elderly patients with reversible obstructive airways disease. Respir Med 1998; 92: 562–7

    Article  PubMed  CAS  Google Scholar 

  15. Maesen FP. Eformoterol versus salbutamol in patients with ROAD. Br J Clin Pract 1995; Suppl. 81: 8–10

    Google Scholar 

  16. Sybrecht GW. Inhaled formoterol was effective and safe treatment in COPD patients [abstract]. Eur Respir J 1999; 14: 379s

    Google Scholar 

  17. Kaushik ML, Kashyap S, Bansal SK, et al. Effectiveness of salmeterol in stable COPD. Indian J Chest Dis Allied Sci 1999; 41: 207–12

    PubMed  CAS  Google Scholar 

  18. Ulrik CS. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study. Thorax 1995; 50: 750–4

    Article  PubMed  CAS  Google Scholar 

  19. Boyd G, Morice AH, Pounsford JC, et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10: 815–21

    PubMed  CAS  Google Scholar 

  20. Jones PW, Bosh TK, in association with an international study group. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283–9

    PubMed  CAS  Google Scholar 

  21. Schmitz E, Hurter T, Ochs JG, et al. Steigerung der korperlichen Leistungsfahigkeit unter Wirkung von Salmeterol. Pneumologie 1994; 48: 12–5

    PubMed  CAS  Google Scholar 

  22. Newman AM, Wiggins J, Smith M, et al. Salmeterol xinofoate (100 mcg bd) in the treatment of chronic obstructive pulmonary airways disease. Eur Respir J 1996; 9 Suppl. 23: 183s

    Google Scholar 

  23. Vervloet D, Ekström T, Pela R, et al. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease. Respir Med 1998; 92: 836–42

    Article  PubMed  CAS  Google Scholar 

  24. Tolep K, Lando Y, D’Alonzo GE. Rethinking inhalative therapy for outpatients with chronic obstructive pulmonary disease. Curr Pulm Med 1997; 4: 93–100

    Article  Google Scholar 

  25. Chapman KR. Clinical implications of anticholinergic bronchodilator therapy in COPD. Res Clin Forums 1991; 13(2): 43–50

    Google Scholar 

  26. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S72–120

    Google Scholar 

  27. Matera MG, Cazzola M, Vinciguerra A, et al. A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1995; 8: 267–71

    Article  PubMed  CAS  Google Scholar 

  28. Anderson W, Wisniewski M, Barbee R, et al. A comparison of serevent and ipratropium on pulmonary function in COPD patients reversible to ipratropium [abstract]. Am J Respir Crit Care Med 1997; 155: A278

    Google Scholar 

  29. Ikeda A, Nishimura K, Koyama H, et al. Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. Thorax 1995; 50: 62–6

    Article  PubMed  CAS  Google Scholar 

  30. Minette A, Marcq M. Oxitropium bromide (Ba 253), an advance in the field of anticholinergic bronchodilating treatments. Rev Inst Hyg Mines (Hasselt) 1979; 34: 115–23

    CAS  Google Scholar 

  31. Cazzola M, Matera MG, Di Perna F, et al. A comparison of bronchodilating effects of salmeterol and oxitropium bromide in stable chronic obstructive pulmonary disease. Respir Med 1998; 92: 354–7

    Article  PubMed  CAS  Google Scholar 

  32. Patakas D, Andreadis D, Mavrofridis E, et al. Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease. Respir Med 1998; 92: 1116–21

    Article  PubMed  CAS  Google Scholar 

  33. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957–65

    Article  PubMed  CAS  Google Scholar 

  34. Wadbo M, Löfdahl C-G, Larsson K, et al. A placebo-controlled comparison of the effects of formoterol and ipratropium bromide in patients with COPD [abstract]. EurRespir J 1999; 14: 381s

    Google Scholar 

  35. Stahl E, Wadbo M, Löfdahl C-G, et al. Quality of life and correlations with walking distance/lung function in patients with moderate to severe COPD [abstract]. EurRespir J 1999; 14: 521s

    Google Scholar 

  36. Dahl R, Greefhorst APM, Nowak D, et al. Comparison of the efficacy and safety of inhaled formoterol and ipratropium bromide in patients with COPD [abstract]. Am J Respir Crit Care Med 2000; 161: A489

    Google Scholar 

  37. Combivent Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. Chest 1994; 105: 1411–9

    Article  Google Scholar 

  38. Matera MG, Caputi M, Cazzola M. A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease. Respir Med 1996; 90: 497–9

    Article  PubMed  CAS  Google Scholar 

  39. Sichletidis L, Kottakis J, Marcou S, et al. Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD. Int J Clin Pract 1999; 53: 185–8

    PubMed  CAS  Google Scholar 

  40. Cazzola M, Matera MG, Di Perna F, et al. Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD. Respir Med 1999; 93: 909–11

    Article  PubMed  CAS  Google Scholar 

  41. Cazzola M, Di Perna F, Centanni S, et al. Acute effect of pre-treatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary disease. Thorax 1999; 54: 1083–6

    Article  PubMed  CAS  Google Scholar 

  42. van Noord JA, de Munck DRAJ, Bantje ThA, et al. Long term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000; 15: 878–85

    Article  PubMed  Google Scholar 

  43. Chapman K, Kuipers AF, Goldstein R, et al. Addition of salmeterol 50 µg bid to anticholinergic treatment in COPD [abstract]. Am J Respir Crit Care Med 1999; 159: A523

    Google Scholar 

  44. Cazzola M, Di Perna F, Califano C, et al. Incremental benefit of adding oxitropium bromide to formoterol in patients with stable COPD. Pulm Pharmacol Ther 1999; 12: 267–71

    Article  PubMed  CAS  Google Scholar 

  45. Newnham DM, Dhillon DP, Winter JH, et al. Bronchodilator reversibility to low and high doses of terbutaline and ipratropium bromide in patients with chronic obstructive pulmonary disease. Thorax 1993; 48: 1151–5

    Article  PubMed  CAS  Google Scholar 

  46. Janson C, Chinn S, Jarvis D, et al. Physician-diagnosed asthma and drug utilization in the European Community Respiratory Health Survey. Eur Respir J 1997; 10: 1795–802

    Article  PubMed  CAS  Google Scholar 

  47. Vaz Fragoso CA, Miller MA. Review of the clinical efficacy of theophylline in the treatment of chronic obstructive pulmonary disease. Am Rev Respir Dis 1993; 147: S40–7

    PubMed  CAS  Google Scholar 

  48. Whiting B, Kelman AW, Barclay J, et al. Modelling theophylline response on individual patient with chronic bronchitis. Br J Pharmacol 1981; 12: 481–7

    Article  CAS  Google Scholar 

  49. Holford N, Black P, Couch R, et al. Theophylline target concentration in severe airways obstruction: 10 or 20 mg/L? A randomised concentration-controlled study. Clin Pharmacokinet 1993; 25: 495–505

    Article  PubMed  CAS  Google Scholar 

  50. Jenne JW, Siever JR, Druz WS, et al. The effect of maintenance theophylline therapy on lung work in severe chronic obstructive pulmonary disease while standing and walking. Am Rev Respir Dis 1984; 130: 600–5

    PubMed  CAS  Google Scholar 

  51. Cazzola M, Donner CF, Matera MG. Long-acting β2-agonists and theophylline in stable chronic obstructive pulmonary disease. Thorax 1999; 54: 730–6

    Article  PubMed  CAS  Google Scholar 

  52. Di Lorenzo G, Morici G, Drago A, et al. Tolerability and effects on quality of life of inhaled salmeterol 50 µg b.i.d. and oral twice daily dose-titrated theophylline in a patient population with mild to moderate chronic obstructive pulmonary disease: SLMT02 Italian Study Group. Clin Ther 1998; 20: 1130–48

    Article  PubMed  Google Scholar 

  53. Taccola M, Bancalari L, Ghignoni G, et al. Salmeterol versus slow-release theophylline in patients with reversible obstructive pulmonary disease. Monaldi Arch Chest Dis 1999; 54: 302–6

    PubMed  CAS  Google Scholar 

  54. Broseghini C, Testi R, Ingrassi M, et al. Short-term comparison between salmeterol and theophylline in stable COPD [abstract]. Am J Respir Crit Care Med 1997; 155: A589

    Google Scholar 

  55. Giessel G, ZuWallack R, Cook C, et al. A comparison of serevent and theophylline on pulmonary function in COPD patients [abstract]. Am J Respir Crit Care Med 1999; 159: A523

    Google Scholar 

  56. Knobil K, Emmett A, Reily D, et al. Combination therapy with salmeterol and theophylline for COPD [abstract]. Am J Respir Crit Care Med 2000; 161: A489

    Google Scholar 

  57. Kristufek P, Amgott TR, Levine B, et al. Comparison of the efficacy and safety of inhaled formoterol dry powder and oral slow-release theophylline in patients with COPD [abstract]. Am J Respir Crit Care Med 2000; 161: A489

    Google Scholar 

  58. Amgott TR, Kristufek P, Levine B, et al. Effect of inhaled formoterol dry powder and oral slow-release theophylline on peak expiratory flow in patients with COPD [abstract]. Am J Respir Crit Care Med 2000; 161: A582

    Google Scholar 

  59. Melani AS, Pirrelli M, Di Gregorio A. Effects of inhaled salmeterol and orally dose-titrated theophylline on exercise capacity of stable COPD patients [abstract]. Eur Respir J 1996; 9 Suppl. 23: 391s

    Google Scholar 

  60. Costello J. Cardiac effects of β-agonists in patients with COPD. Chest 1998; 114: 353–4

    Article  PubMed  CAS  Google Scholar 

  61. Sarubbi B, Esposito V, Ducceschi V, et al. Effect of blood gas derangement on QTc dispersion in severe chronic obstructive pulmonary disease: evidence of an electropathy? Int J Cardiol 1997; 58: 287–92

    Article  PubMed  CAS  Google Scholar 

  62. Conradson TB, Eklundh G, Olofsson B, et al. Cardiac arrhythmias in patients with mild-to-moderate obstructive pulmonary disease: comparison of beta-agonist therapy alone and in combination with a xanthine derivative, enprophylline or theophylline. Chest 1985; 88: 537–42

    Article  PubMed  CAS  Google Scholar 

  63. Stewart AG, Waterhouse JC, Howard T. The QTc interval, autonomic neuropathy and mortality in hypoxaemic COPD. Respir Med 1995; 89: 79–84

    Article  PubMed  CAS  Google Scholar 

  64. Bremner P, Burgess CD, Crane J, et al. Cardiovascular effects of fenoterol under conditions of hypoxaemia. Thorax 1992; 47: 814–7

    Article  PubMed  CAS  Google Scholar 

  65. Cazzola M, Imperatore F, Salzillo A, et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998; 114: 411–5

    Article  PubMed  CAS  Google Scholar 

  66. Till MD. Cardiovascular and metabolic effects of eformoterol in adults. Br J Clin Pract 1995; Suppl. 81: 2–3

    Google Scholar 

  67. Tranfa CM, Pelaia G, Grembiale RD, et al. Short-term cardiovascular effects of salmeterol. Chest 1998; 113: 1272–6

    Article  PubMed  CAS  Google Scholar 

  68. Taylor DR, Sears MR, Cockcroft DW. The beta agonist controversy. Med Clin North Am 1996; 80: 719–48

    Article  PubMed  CAS  Google Scholar 

  69. Lipworth BJ. Airway subsensitivity with long-acting beta2-agonists: is there cause for concern? Drug Saf 1997; 16: 295–308

    Article  PubMed  CAS  Google Scholar 

  70. Cazzola M, Di Perna F, Noschese P, et al. Effects of a pre-treatment with conventional doses of formoterol, salmeterol or oxitropium bromide on the dose-response curves to salbutamol in patients suffering from partially reversible COPD. Eur Respir J 1998; 11: 1337–41

    Article  PubMed  CAS  Google Scholar 

  71. Bjermer L, Larsson L. Long-acting β2-agonists: how are they used in an optimal way? Respir Med 1997; 91: 578–91

    Article  Google Scholar 

  72. Cockcroft DW. Inhaled β2-agonists and airway responses to allergen. J Allergy Clin Immunol 1998; 102: S96–9

    Article  PubMed  CAS  Google Scholar 

  73. Anderson W, Fling M, Xue Z, et al. The lack of effect of beta2-adrenoceptor polymorphisms on response to salmeterol in COPD [abstract]. Am J Respir Crit Care Med 2000; 161: A571

    Google Scholar 

  74. Cazzola M, Vinciguerra A, Di Perna F, et al. Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease. Respir Med 1998; 92: 1012–6

    Article  PubMed  CAS  Google Scholar 

  75. Jenne JW. Whatrole for theophylline? Thorax 1994; 49: 97–100

    Article  PubMed  CAS  Google Scholar 

  76. Jubrin A, Gross N, Ramsdell JW, et al. Comparative cost-effectiveness analysis of theophylline and ipratropium bromide in patients with COPD: a three-center study. Chest 1993; 103: 678–84

    Article  Google Scholar 

  77. Lanes SF, Lanza LL, Wentworth CE. Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol. Am J Respir Crit Care Med 1998; 158; 857–61

    PubMed  CAS  Google Scholar 

  78. Cazzola M, Matera MG. Should long-acting β2-agonists be considered an alternative first choice option for the treatment of stable COPD? Respir Med 1999; 93: 227–9

    Article  PubMed  CAS  Google Scholar 

  79. Ferguson GT, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 1993; 320: 1017–22

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pneumology and Allergology, A. Cardarelli Hospital, Naples, Italy

    Mario Cazzola

  2. S. Maugeri Foundation, Institute of Care and Research, Medical Centre of Rehabilitation, Division of Pneumology, Veruno, Italy

    Claudio Ferdinando Donner

Authors
  1. Mario Cazzola
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudio Ferdinando Donner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mario Cazzola.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cazzola, M., Donner, C.F. Long-Acting β2 Agonists in the Management of Stable Chronic Obstructive Pulmonary Disease. Drugs 60, 307–320 (2000). https://doi.org/10.2165/00003495-200060020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200060020-00005

Keywords

Search

Navigation